FDA approves landmark pancreatic cancer drug that's shown to improve survival

FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases.